Skip to content
Screener

ADMA Biologics ADMA Q2 2026 earnings

Reported August 5, 2026 · After market close

Revenue$124.4MMiss by $949.5K
EPS$0.16Miss by $0.00
Revenue estimate$125.3M
EPS estimate$0.16
“Our second quarter results reflect strong execution across the business and demonstrate the power of ASCENIV's growth trajectory. ASCENIV continued to outperform, supported by increasing physician adoption, broader prescriber engagement, new patient starts and higher patient utilization. Growth in ASCENIV utilization accelerated in the quarter, with June delivering the strongest sequential month-over-month utilization growth since the first half of 2024. BIVIGAM demand continued to stabilize during the quarter, resulting in sequential improvement in utilization and revenue. Together, these trends reinforce our confidence in sustained growth throughout the balance of 2026.”
Adam Grossman

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$138.1M
EPS estimate$0.19

Financials

Q2 2026

Income statement

See full
Revenue$124.4M+2.0%
Gross profit$86.3M+28.3%
Operating income$52.4M+22.5%
Net income$37.8M+10.5%
EPS (diluted)$0.16+14.3%

Balance sheet

See full
Cash & equivalents$136.0M+50.7%
Total debt$203.9M+1,855%
Total equity$408.2M+2.5%
Total assets$684.2M+22.5%

Cash flow

See full
Operating cash flow$29.5M+39.7%
CapEx$2.3M-6.9%
Free cash flow$27.3M+45.8%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$1.93B-46.3%
Enterprise value$2B-43.3%
P/E11.4×-5.8×
P/S3.8×-3.8×

Profitability

See full
Gross margin64.7%+11.7pp
Operating margin43.8%+11.0pp
Net margin33%-11.1pp
FCF margin22.7%+8.9pp

Returns & leverage

See full
Return on equity41.9%-29.3pp
Debt / equity0.5×+0.5×
Current ratio7×+1.6×

Segments

By product

See full
ASCENIV$102.9M+23.5%
BIVIGAM$19.4M-48.5%
Intermediates And Other$1.3M+41.4%

By segment

See full
ADMA Bio Manufacturing$123.6M+1.4%
Plasma Collection Centers$723.0K—

FAQ

When did ADMA Biologics report Q2 2026 earnings?
ADMA Biologics (ADMA) reported Q2 2026 earnings on August 5, 2026 after market close.
What were ADMA Biologics's Q2 2026 revenue and EPS?
ADMA Biologics reported revenue of $124.4M and eps of $0.16 for Q2 2026.
Did ADMA Biologics beat estimates in Q2 2026?
Revenue missed the consensus estimate of $125.3M by $949.5K. EPS missed the consensus estimate of $0.16 by $0.00.
How did ADMA Biologics's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 2.0% from $122.0M a year earlier and eps grew 6.7% from $0.15.
Where can I find ADMA Biologics's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001140361-26-031423) and the 10-Q periodic report (0001140361-26-031445) directly on SEC EDGAR. The filing index links above go to sec.gov.